Hepatopathy-thrombocytopenia syndrome (HTS) after actinomycin-D therapy: Report of three cases and review of the literature

Pediatric Hematology and Oncology

Volumn 28, Issue 3, 2011, Pages 237-243

  Farruggia, Piero ^a   MacAluso, Alessandra ^a   Tropia, Serena ^a   Di Marco, Floriana ^a   Russo, Delia ^a   Grigoli, Antonella ^a   Trizzino, Antonino ^a   D'Angelo, Paolo ^a  

^a ARNAS   (Italy)

Author keywords

actinomycin D; hepatopathy thrombocytopenia syndrome; vein occlusive disease; Wilms Tumor

Indexed keywords

DACTINOMYCIN; VINCRISTINE;

ANAMNESIS; ARTICLE; ASCITES; BLOOD EXAMINATION; CASE REPORT; CHILD; CLINICAL FEATURE; FEMALE; FEVER; HEPATIC SINUSOIDAL OBSTRUCTIVE SYNDROME; HEPATOMEGALY; HUMAN; INFANT; JAUNDICE; LABORATORY TEST; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; MALE; NEPHROBLASTOMA; PRESCHOOL CHILD; THROMBOCYTOPENIA; VEIN OCCLUSION; WEIGHT GAIN;

ANTIBIOTICS, ANTINEOPLASTIC; DACTINOMYCIN; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; REVIEW LITERATURE AS TOPIC; SYNDROME; THROMBOCYTOPENIA; WILMS TUMOR;

EID: 79952507259     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.535118     Document Type: Article

References (25)

1. Lee JL, Gooley T, Bensinger W, et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999;5:306-315.
2. Hogan WJ, Maris M, Storer B, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood. 2004;103:78-84. (Pubitemid 38029921)
3. Cecen E, Kamer MU, Ozguven A, et al. Veno-Occlusive Disease in a child with rhabdomyosarcoma after conventional therapy: report of a case and review of the literature. Pediatr Hematol Oncol. 2007;24:615-621. (Pubitemid 350293538)
4. Kanwar VS, Albuquerque ML, Ribeiro RC, et al. Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Med Pediatr Oncol. 1995;24:334-340.
5. Raine J, Bowman A, Wallendszus K, Pritchard J. Hepatopathy- thrombocytopenia syndrome;acomplication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Children's Cancer Study Group. J Clin Oncol. 1991;9:268-273.
6. Bisogno G, de Kraker J, Weirich A, et al. Veno-occlusive disease of the liver in children treated for Wilms tumor. Med Pediatr Oncol. 1997;29:245-251. (Pubitemid 27329122)
7. Shannon A, Smith J, Nagel K, et al. Selective thrombocytopenia in children with Wilms tumor: an immune-mediated effect of dactinomycin? Med Pediatr Oncol. 2003;41:483-485. (Pubitemid 37229451)
8. Khatua S, Nair CN, Ghosh K. Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. J Pediatr Hematol Oncol. 2004;26:777-779. (Pubitemid 39577732)
9. Jagt CT, Zuckermann M, Kate FT, et al. Veno-occlusive disease as a complication of preoperative chemotherapy for Wilms tumor: a clinico-pathological analysis. Pediatr Blood Cancer. 2009;53:1211-1215.
10. McDonald GB. Veno-occlusive disease of the liver following marrow transplantation. Marrow Transpl Rev. 1994;3:49-56.
11. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin- associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res. 2007;31:599-604. (Pubitemid 46578145)
12. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310-2314. (Pubitemid 34525414)
13. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23:589-599. (Pubitemid 26087175)
14. DeLeve LD, McCuskey RS, Wang X, et al. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology. 1999;29:1779-1791. (Pubitemid 29247052)
15. Tchilian EZ, Beverley PCL, Young BD, Watt SM. Molecular cloning of two isoforms of the murine homolog of the myeloid CD33 antigen. Blood. 1994;83:3188-3198. (Pubitemid 24158463)
16. Gao Z, McAlister VC, Williams GM. Repopulation of liver endothelium by bone marrow-derived cells. Lancet. 2001;357:932-933. (Pubitemid 32247285)
17. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004;104:1574-1577. (Pubitemid 39166540)
18. Falanga A, Marchetti M, Vignoli A, Barbui T. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cells macro-and micro-vessels. Blood. 2000;96:53a.
19. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337-4343. (Pubitemid 35429671)
20. Lannoy D, Decaudin B, Grozieux de Laguérenne A, et al. Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J Clin Pharm Ther. 2006;31:389-392. (Pubitemid 44060204)
21. Cefalo MG, Maurizi P, Arlotta A, et al. Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies. Paediatr Drugs. 2010;12:277-284.
22. Mertens R, Brost H, Granzen B, Nowak-Göttl U. Antithrombin treatment of severe hepatic venoocclusive disease in children with cancer. Eur J Pediatr. 1999;158(Suppl 3):154-158.
23. Haussmann U, Fischer J, Eber S, et al. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy. Haematologica. 2006;91:795-800. (Pubitemid 44014546)
24. Ikezoe T, Togitani K, Komatsu N, et al. Successful treatment of sinusoidal obstructive syndromeafter hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant. 2010;45:783-785.
25. D'Antiga L, Baker A, Pritchard J, et al. Veno-occlusive disease with multi-organ involvement following actinomycin-D. Eur J Cancer. 2001;37:1141-1148.